Healthcare / Drug Manufacturers - Specialty & GenericUpdated 2026-05-10 22:07 UTC

ZTS stock hub

Zoetis is a dominant, mature compounder in the animal health space, benefiting from high switching costs, robust brand loyalty, and significant scale economies. With consistent mid-single-digit revenue growth and high operating margins (~37%), it generates strong and predictable free cash flow.

Read full analysis Valuation Archive

Fair value midpoint

$140

$109 - $170

Upside to midpoint

+81.7%

Based on latest report

Confidence

88/100

Data quality and model convergence

Market cap

$32.3B

NYSE

Our take

Research highlights

What our analysis says

Pulled from the latest published report. The full reasoning lives under /analysis.

Biggest opportunity

Bull case

Bull: Pet humanization trends accelerate alongside successful pipeline launches, driving revenue CAGR above 5% and sparking multiple expansion.

Strong Buy. Zoetis represents an extreme value dislocation for a premier mature compounder. The $139.77 composite fair value provides massive upside against irrational market pessimism.

Market data

Live price

Current market quote for this ticker.

Current price

ZTS

In the news

Latest news · ZTS

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Analysis map

Jump into the research surface

These links all point into /analysis/*, so a hub rollback leaves the report reader and legacy redirects live.

Forecast

Targets

Bull, base, and bear cases with expected-return framing.

Valuation

Models

Fair-value bridge, DCF, owner earnings, and peer multiples.

Sensitivity

Grid

Cost-of-equity and terminal-growth stress table.

Risks

Bear case

Kill scenarios, soft-pass flags, and downside catalysts.

Earnings

Decision tree

Next earnings setup and beat / inline / miss thresholds.

Position sizing

Checkpoints

Entry, exit, conviction, and quarterly monitoring rules.

Financials

History

Revenue, margins, cash flow, and balance-sheet context.

Peers

Comps

Relative valuation and profitability against the cohort.

Moat

Durability

Economic-profit evidence and competitive advantage risk.

Industry cycle

Context

Sector phase, capital cycle, and secular tailwinds.

Scorecard

Factors

Six-factor overlay and 9-category weighted scorecard.

Recommendation

Verdict

Final action, action steps, opportunity, and biggest risk.

Perspectives

Lenses

Growth, value, and income investor reads.

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E10.3

P25 12.3P50 18.4P75 33.1

Trailing P/E0

P25 14.9P50 23.2P75 38.5

ROE67.7

P25 -105.6P50 -46.5P75 -3.1

ROIC27.8

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Our take

Indicator catalog

All ZTS market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

278

Groups with data

Currency

USD

Showing 278 of 278 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001555280
Company name	Zoetis Inc.
Country	United States
Country code	US
Cusip	98978V103
Employees	14,500
Employees Change	700%
Employees Change Percent	5.07
Enterprise value	$42B
Exchange	NYSE
Financial currency	USD
First seen	2026-05-09
In Index	SP500
Industry	Drug Manufacturers - Specialty & Generic
IPO Date	2013-02-01
Isin	US98978V1035
Last refreshed	2026-05-10
Market cap	$34.7B
Market cap category	Large-Cap
Price	$82.83
Price currency	USD
Rev Per Employee	657,310.34x
Sector	Healthcare
Sic	2834
Symbol	ZTS
Website	https://www.zoetis.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	7.69%
EV Earnings	15.73x
EV Sales Forward	4.17x
EV/EBIT	11.57x
EV/EBITDA	10.32x
EV/FCF	18.79x
EV/Sales	4.41x
FCF yield	6.44%
Forward P/E	11.76x
P/B ratio	10.77x
P/E ratio	13.56x
P/S ratio	3.64x
PE Ratio10 Y	36.43x
PE Ratio3 Y	30.21x
PE Ratio5 Y	34.84x
PEG ratio	1.71x
PS Forward	3.44x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	38.12%
EBITDA Margin	42.74%
FCF margin	23.47%
Gross margin	71.84%
Gross Profit	$6.8B
Gross Profit Growth	4.18%
Gross Profit Growth Q	2.59%
Gross Profit Growth3 Y	6.75%
Gross Profit Growth5 Y	7%
Net Income	$2.7B
Net Income Growth	7.35%
Net Income Growth Q	-0.17%
Net Income Growth Years	10%
Net Income Growth3 Y	8.86%
Net Income Growth5 Y	8.54%
Pretax Margin	35.1%
Profit Margin	28.03%
Profit Per Employee	$184,276
Profitable Years	16
ROA	15.52
Roa5y	13.76
ROCE	27.73
ROE	67.75
Roe5y	52.61
ROIC	27.8
Roic5y	28.07

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	6.63%
Cagr1y	-46.1%
Cagr3y	-22.73%
Cagr5y	-12.68%
Div CAGR10	19.19%
Div CAGR3	13.74%
Div CAGR5	18.01%
EPS Growth	11.01
EPS Growth Q	5.97
EPS Growth Quarters	7
EPS Growth Years	10
EPS Growth3 Y	11.4
EPS Growth5 Y	10.48
FCF Growth	2.62%
FCF Growth Q	-13.65%
FCF Growth3 Y	15.34%
FCF Growth5 Y	5.87%
OCF Growth	-2.89%
OCF Growth Q	-22.14%
OCF Growth10 Y	15.59%
OCF Growth3 Y	9.04%
OCF Growth5 Y	5.67%
Revenue Growth	2.88x
Revenue Growth Q	2.91x
Revenue Growth Quarters	41x
Revenue Growth Years	10x
Revenue Growth3 Y	5.6x
Revenue Growth5 Y	6.33x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.65
Assets	$15.2B
Cash	$1.9B
Current Assets	$6.5B
Current Liabilities	$2.1B
Debt	$9.3B
Debt EBITDA	$2.21
Debt Equity	$2.86
Debt FCF	$4.14
Equity	$3.2B
Interest Coverage	15.8
Liabilities	$11.9B
Long Term Assets	$8.7B
Long Term Liabilities	$9.9B
Net Cash	$-7.3B
Net Cash By Market Cap	$-21.06
Net Debt EBITDA	$1.8
Net Debt Equity	$2.26
Net Debt FCF	$3.27
Tangible Book Value	$-504M
Tangible Book Value Per Share	$-1.2
WACC	7.52

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	3.15
Inventory Turnover	1.09
Net Working Capital	$2.5B
Quick ratio	1.68
Working Capital	$4.4B
Working Capital Turnover	$2.76

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	3.25%
Dividend Growth	10.52%
Dividend Growth Years	13%
Dividend per share	$2.12
Dividend Years	14
Dividend Yield	2.56%
Ex Div Date	2026-04-20
Last Dividend	$0.53
Payout Frequency	Quarterly
Payout Ratio	33.73%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	90.08%
1Y total return	-46.08%
200-day SMA	131
3Y total return	-53.88%
50-day SMA	117.1
50-day SMA vs 200-day SMA	50under200
5Y total return	-49.22%
All Time High	249.3
All Time High Change	-66.77%
All Time High Date	2021-12-30
All Time Low	28.14
All Time Low Change	194.4%
All Time Low Date	2014-04-15
ATR	4.72
Beta	0.86
Beta1y	0.69
Beta2y	0.39
Ch YTD	-34.17
High	87.58
High52	172.2
High52 Date	2025-06-03
High52ch	-51.91%
Low	81.1
Low52	81.1
Low52 Date	2026-05-08
Low52ch	2.13%
Ma50ch	-29.29%
Premarket Change Percent	0.17
Premarket Price	$87.46
Premarket Volume	61,426
Price vs 200-day SMA	-36.76%
RSI	13.66
RSI Monthly	26.38
RSI Weekly	22.1
Sharpe ratio	-1.7x
Sortino ratio	-1.78
Total Return	5.81%
Tr YTD	-33.6
Tr1m	-28.78%
Tr1w	-27.44%
Tr3m	-34.71%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	12
Analyst Count Top	3
Analyst Price Target Top	$147
Analyst Ratings	Buy
Analyst Ratings Top	Hold
Earnings EPS Estimate	$1.61
Earnings EPS Estimate Growth	8.78
Earnings Revenue Estimate	2,300,850,760x
Earnings Revenue Estimate Growth	3.64x
Operating Income	$3.6B
Operating Income Growth	6.32
Operating Income Growth Q	0.98
Operating Income Growth3 Y	8.11
Operating Income Growth5 Y	7.64
Operating margin	38.12
Price target	$145
Price Target Change	$75.06
Price Target Change Top	$77.07

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	418,397,996%
Float Percent	99.8%
Net Borrowing	2,311,000,000
Shares Insiders	0.09%
Shares Institutions	104.45%
Shares Out	419,228,118
Shares Qo Q	-3.69%
Shares Yo Y	-3.25%
Short Float	3.23%
Short Ratio	3.69
Short Shares	3.22

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$2.1B
Average Volume	5,576,323.3x
Bv Per Share	7.69
CAPEX	$-553M
Ch10y	74.97
Ch1m	-29.08
Ch1w	-27.44
Ch1y	-46.9
Ch3m	-34.99
Ch3y	-55.52
Ch5y	-51.72
Ch6m	-31.11
Change	-5.13%
Change From Open	-5.14
Close	87.31
Days Gap	0.01
Depreciation Amortization	441,000,000
Dollar Volume	1,423,196,656.2
Earnings Date	2026-05-07
Earnings Time	bmo
EBIT	$3.6B
EBITDA	$4.1B
EPS	$6.11
F Score	7
FCF	$2.2B
FCF EV Yield	5.32x
FCF Per Share	$5.34
Financing CF	-2,033,000,000
Fiscal Year End	December
Founded	1,952
Goodwill	2,778,000,000
Graham Number	32.50873
Graham Upside	-60.75
Income Tax	$673M
Investing CF	-632,000,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-07
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-02-12
Lynch Fair Value	$52.13
Lynch Upside	-37.06
Ma150	124.7
Ma150ch	-33.57%
Ma20	113.9
Ma20ch	-27.3%
Net CF	148,000,000
Next Earnings Date	2026-08-04
Open	87.32
Optionable	Yes
P FCF Ratio	15.52
P OCF Ratio	12.45
Payment Date	2026-06-02
Position In Range	26.7
Post Close	82.83
Postmarket Change Percent	-0.01
Postmarket Price	$82.82
Ppne	4,001,000,000
Pre Close	87.31
Price Date	2026-05-08
Price EBITDA	$8.52
Relative Volume	3.08x
Revenue	9,531,000,000x
SBC By Revenue	0.95x
Share Based Comp	91,000,000
Tax By Revenue	7.06x
Tax Rate	20.12%
Tr6m	-30.52%
Us State	New Jersey
Views	225
Volume	17,182,140
Z Score	6.21

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

9/10

Business quality stays separate from stock attractiveness.

Forward P/E

10.3x

Valuation uses the full report model stack, not a single multiple.

Next action

Strong Buy

Final action steps are kept in the recommendation tab.

Our take

Income

ZTS dividend yield, growth & safety

Yield, payout sustainability, and the multi-year growth streak.

Dividend yield

+2.6%

$2.12 annual per share

Payout ratio

+33.7%

Share of earnings returned as dividends. Below 60% is generally sustainable.

5Y dividend CAGR

+18.0%

13 consecutive years of growth

Total shareholder yield

+5.8%

Next ex-dividend date: 2026-04-20

Performance

ZTS stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns ZTS?

Insider, institutional, and short-interest positioning.

Institutional ownership

+104.4%

Float: +99.8% of shares outstanding

Insider ownership

+0.1%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

ZTS momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

13.7

Below 30: short-term oversold

Price vs 200-day MA

-36.8%

50/200-day relationship not available

Beta (5Y)

0.86

Moves roughly with the market

Sharpe ratio

-1.70

Risk-adjusted return — higher is better; >1.0 is solid.

Peers

ZTS vs. sector cohort

Currency-neutral comparison: P/E, P/S, ROIC, 5Y revenue CAGR, and 1Y total return. Market-cap column appears only when every peer reports in the same currency.

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
AAPL	Apple Inc.	4.3T	35.6x	9.5x	104.3%	+6.8%	+50.1%	매도
ABNB	Airbnb Inc.	84B	34.7x	6.6x	15.9%	+29.9%	+14.9%	보유
ADBE	Adobe Inc.	102.3B	14.8x	4.2x	63.3%	+12.3%	-34.3%	적극 매수

Questions

About ZTS

Hub-level FAQ points readers to the deeper analysis pages.

What is the current ZTS stock rating?

Zoetis Inc. is currently shown with Strong Buy in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full ZTS analysis?

The full report lives at /stocks/ZTS/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for ZTS?

The latest report frames ZTS around $109 to $170. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the ZTS page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.